AAVnerGene

AAVnerGene is a private, pre-revenue biotech tools and services company positioned as an enabler in the rapidly growing gene therapy sector. Its core value proposition lies in three proprietary technology platforms: the AAVone single-plasmid production system for higher-yield, lower-cost AAV manufacturing; the ATHENA capsid engineering platform for creating novel, tissue-specific AAV vectors; and the AAV-Q assay platform for sensitive quality control. By offering a comprehensive suite of plasmids, viruses, biosensors, and custom services, AAVnerGene aims to be a critical partner for academic, biotech, and pharmaceutical entities navigating the complexities of AAV-based gene therapy development.

AAVone single-plasmid AAV production system for high-yield manufacturing; ATHENA capsid engineering platform for creating novel, tissue-targeted AAV vectors; AAV-Q assay platform for ultra-sensitive TCID50 and rcAAV quality control testing.

AAVnerGene competes with established AAV service providers (e.g., Vigene, Vector Biolabs), plasmid and virus suppliers (Addgene, SignaGen), and other capsid engineering startups. Its differentiation lies in the integration of its three proprietary platforms aimed at improving yield, targeting, and analytics within a single vendor ecosystem.